Preclinical studies havesuggested that in addition to stimulating adaptive immune responses against tumor cells,avelumab may also engage innate effector cell functions through its wild-type Fc region,unlike other approved anti–PD-L1/PD-1 antibodies.12–14. This evidence concerns the gene CD274 and neoplasm.